0001816514-21-000002.txt : 20210204 0001816514-21-000002.hdr.sgml : 20210204 20210204133639 ACCESSION NUMBER: 0001816514-21-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210204 DATE AS OF CHANGE: 20210204 EFFECTIVENESS DATE: 20210204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Initial Therapeutics, Inc. CENTRAL INDEX KEY: 0001816514 IRS NUMBER: 850692453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-371190 FILM NUMBER: 21590337 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 781-367-5419 MAIL ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 FORMER COMPANY: FORMER CONFORMED NAME: Opal Biosciences, Inc. DATE OF NAME CHANGE: 20200630 D/A 1 primary_doc.xml X0708 D/A LIVE 0001816514 Initial Therapeutics, Inc. 230 PARK AVENUE, SUITE 2800 NEW YORK NY NEW YORK 10169 781-367-5419 DELAWARE Opal Biosciences, Inc. Corporation true 2020 Spiros Liras c/o Initial Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Executive Officer Director Seth Harrison c/o Initial Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Michael Ehlers c/o Initial Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director James H. Doudna Cate c/o Initial Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Rajesh Chopra c/o Initial Therapeutics, Inc. 230 Park Avenue, Suite 2800 New York NY NEW YORK 10169 Director Biotechnology Decline to Disclose 06b true 0001816514-20-000001 2020-07-02 false true false 0 75000000 3800000 71200000 false 1 0 0 0 false Initial Therapeutics, Inc. /s/ Sprios Liras Sprios Liras Chief Executive Officer 2021-02-03